To further improve the response rate, RIPK2 inhibitors can be introduced for the reason that the associated “molecular inflammation” is the driving force behind IBC tumorigenesis and metastasis (Zare et al., 2018). The gene discussed is RIPK2; the disease is inflammatory breast carcinoma.